medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2025, Number 5

<< Back

Ginecol Obstet Mex 2025; 93 (5)

Biomarkers: A promising alternative for the early detection of the risk of preeclampsia

Anaya RAF

Language: Spanish
References: 25
Page: 184-191
PDF size: 353.90 Kb.


ABSTRACT

Background: Preeclampsia, a major cause of maternal morbidity and mortality, requires timely diagnosis to initiate strategies to minimize potential complications for mother and child. Recently, there has been increasing interest in the search for biomarkers that can identify the risk of preeclampsia in the early weeks of pregnancy.
Objective: To review the current literature and describe the biomarkers studied for the early diagnosis of pre-eclampsia.
Methodology: PubMed and Lilacs databases were searched using the MeSH terms in English "biomarkers," "diagnosis," and "preeclampsia" and their corresponding Spanish translations to find biomarkers studied for the early diagnosis of preeclampsia.
Results: Fifty-five articles were obtained, of which 38 were excluded due to duplication, irrelevant titles and abstracts, and research protocols; 17 articles were used for analysis and 8 others were used to supplement the discussion.
Conclusions: Biomarkers, especially those related to angiogenesis, are crucial for risk identification and diagnosis of preeclampsia in the early stages of pregnancy. However, their clinical application requires further studies to validate their efficacy.


REFERENCES

  1. ACOG. Obstetrics and Gynecology 2019; 133 (1): 1. https://doi.org/10.1097/aog.0000000000003018

  2. Velumani V, Cárdenas CD, Gutiérrez LSH. Preeclampsia: unamirada a una enfermedad mortal. Revista de la Facultadde Medicina 2021; 64 (5): 7-18. https://doi.org/10.22201/fm.24484865e.2021.64.5.02

  3. Chicana-Muñoz J, Asencio-Cámac M, Galdos-Bejar M, CarreazoNY. Riesgo de preeclampsia en primigestas adolescentes.Ginecol Obstet Mex 2024; 92 (9): 386-95. https://doi.org/10.24245/gom.v92i9.9601

  4. Say L, Chou D, Gemmill A, Tunçalp Ö, et al. Global causesof maternal death: a WHO systematic analysis. Lancet2014; 2 (6): e323-33. https://doi.org/10.1016/s2214-109x(14)70227-x

  5. Alipour J, Payandeh A, Karimi A. Prevalence of maternalmortality causes based on ICD-MM: a systematic reviewand meta-analysis. BMC Pregnancy and Childbirth 2023; 23(1). https://doi.org/10.1186/s12884-023-06142-y

  6. Mosimann B, Amylidi-Mohr SK, Surbek D, Raio L. Firsttrimester screening for preeclampsia. A systematic review.Hypertension in Pregnancy 2019; 39 (1): 1-11. https://doi.org/10.1080/10641955.2019.1682009

  7. Chen Y, Chen Y, Wang X, Chu X, et al. Second trimestermaternal serum D-dimer combined with alpha-fetoproteinand free β-subunit of human chorionic gonadotropinpredict hypertensive disorders of pregnancy: a systematicreview and retrospective case-control study. J Transl Med2021; 19 (1). https://doi.org/10.1186/s12967-021-02718-4

  8. MacDonald TM, Walker SP, Hannan NJ, Tong S, Kaitu’u-LinoTJ. Clinical tools and biomarkers to predict preeclampsia.EBioMedicine 2021; 75: 103780. https://doi.org/10.1016/j.ebiom.2021.103780

  9. Tomkiewicz J, Darmochwał-Kolarz DA. Biomarkers for earlyprediction and management of preeclampsia: a comprehensivereview. Medical Science Monitor 2024; 30. https://doi.org/10.12659/msm.944104

  10. Poon LC, Magee LA, Verlohren S, Shennan A, et al. A literaturereview and best practice advice for second and thirdtrimester risk stratification, monitoring, and managementof pre‐eclampsia. Int J Gynecol Obstet 2021; 154 (S1): 3-31.https://doi.org/10.1002/ijgo.13763

  11. Restrepo FH, Hernández NP, Sánchez LMM, Mejía CR.Biomarcadores moleculares: una nueva herramienta enel diagnóstico de la preeclampsia. Clínica e Investigaciónen Ginecología y Obstetricia 2016; 44 (2): 66-72. https://doi.org/10.1016/j.gine.2016.04.001

  12. Danilo NCC. Preeclampsia: la era de los marcadoresbioquímicos. Rev Cient Cienc Med 2014; 17 (2): 32-38.http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1817-74332014000200008

  13. Camacho-Méndez K, Ventura-Arizmendi E, Zárate A,Hernández-Valencia M. Utilidad de los biomarcadoresséricos involucrados en la fisiopatología de la preeclampsiacomo predictores tempranos de diagnóstico. Perinatologíay Reproducción Humana 2018; 32 (1): 39-42. https://doi.org/10.1016/j.rprh.2018.04.002

  14. Cristodoro M, Messa M, Tossetta G, Marzioni D, et al.First trimester placental biomarkers for pregnancy outcomes.Int J Mol Sciences 2024; 25 (11): 6136. https://doi.org/10.3390/ijms25116136

  15. Lecarpentier E, Gris JC, Cochery-Nouvellon E, Mercier E,et al. Urinary placental growth factor for prediction of placentaladverse outcomes in high-risk pregnancies. ObstetGynecol 2019; 134 (6): 1326-32. https://doi.org/10.1097/aog.0000000000003547

  16. Agrawal S, Shinar S, Cerdeira AS, Redman C, et al. Predictiveperformance of PlGF (Placental Growth Factor) forscreening preeclampsia in asymptomatic women. Hypertension2019; 74 (5): 1124-35. https://doi.org/10.1161/hypertensionaha.119.13360

  17. Duhig KE, Myers JE, Gale C, Girling JC, et al. Placentalgrowth factor measurements in the assessment of womenwith suspected preeclampsia: A stratified analysis of thePARROT trial. Pregnancy Hypertension 2020; 23: 41-7.https://doi.org/10.1016/j.preghy.2020.10.005

  18. Hurrell A, Webster L, Sparkes J, Battersby C, et al. Repeatplacental growth factor-based testing in women withsuspected preterm preeclampsia: a stratified analysisof the PARROT-2 trial. Hypertension 2024. https://doi.org/10.1161/hypertensionaha.123.22411

  19. Kametas NA, Nzelu D, Nicolaides KH. Chronic hypertensionand superimposed preeclampsia: screening and diagnosis.Am J Obstet Gynecol 2021; 226 (2): S1182-95. https://doi.org/10.1016/j.ajog.2020.11.029

  20. De Sá CPN, Jiménez MF, Rosa MW, Arlindo EM, et al.Evaluation of Angiogenic Factors (PlGF and sFlt-1) in preeclampsiadiagnosis. Rev Bras Ginecol Obstet 2020; 42(11): 697-704. https://doi.org/10.1055/s-0040-1713916

  21. Satorres E, Martínez-Varea A, Diago-Almela V. sFlt-1/PlGFratio as a predictor of pregnancy outcomes in twin pregnancies:a systematic review. J Matern Fetal Neonatal Med 2023;36 (2). https://doi.org/10.1080/14767058.2023.2230514

  22. Costa ML, De Carvalho Cavalli R, Korkes HA, Da CunhaFilho EV, et al. Diagnosis and management of preeclampsia:suggested guidance on the use of biomarkers. RevBras Ginecol Obstet 2022; 44 (09): 878-83. https://doi.org/10.1055/s-0042-1744286

  23. Verlohren S, Dröge LA. The diagnostic value of angiogenicand antiangiogenic factors in differential diagnosis of preeclampsia.AJOG 2020; 226 (2): S1048-58. https://doi.org/10.1016/j.ajog.2020.09.046

  24. Kifle MM, Dahal P, Vatish M, Cerdeira AS, et al. The prognosticutility of soluble fms-like tyrosine kinase-1 (sFlt-1)and placental growth factor (PIGF) biomarkers for predictingpreeclampsia: a secondary analysis of data from theINSPIRE trial. BMC Pregnancy and Childbirth 2022; 22 (1).https://doi.org/10.1186/s12884-022-04817-6

  25. Pheiffer C, Dias S, Jack B, Malaza N, et al. Adiponectin as apotential biomarker for pregnancy disorders. Int J Mol Sci2021; 22 (3): 1326. https://doi.org/10.3390/ijms22031326




2020     |     www.medigraphic.com